JP2020514267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514267A5 JP2020514267A5 JP2019533465A JP2019533465A JP2020514267A5 JP 2020514267 A5 JP2020514267 A5 JP 2020514267A5 JP 2019533465 A JP2019533465 A JP 2019533465A JP 2019533465 A JP2019533465 A JP 2019533465A JP 2020514267 A5 JP2020514267 A5 JP 2020514267A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazole
- trifluoromethyl
- carboxamide
- triazole
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437384P | 2016-12-21 | 2016-12-21 | |
| US62/437,384 | 2016-12-21 | ||
| PCT/US2017/067516 WO2018119036A1 (en) | 2016-12-21 | 2017-12-20 | Pyrazole derivatives as malt1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514267A JP2020514267A (ja) | 2020-05-21 |
| JP2020514267A5 true JP2020514267A5 (https=) | 2021-02-04 |
| JP7138641B2 JP7138641B2 (ja) | 2022-09-16 |
Family
ID=61628454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533465A Active JP7138641B2 (ja) | 2016-12-21 | 2017-12-20 | Ｍａｌｔ１阻害剤としてのピラゾール誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10954214B2 (https=) |
| EP (1) | EP3558969B1 (https=) |
| JP (1) | JP7138641B2 (https=) |
| KR (1) | KR102583317B1 (https=) |
| CN (1) | CN110214136A (https=) |
| AR (1) | AR110421A1 (https=) |
| AU (2) | AU2017382185C1 (https=) |
| BR (1) | BR112019012355A2 (https=) |
| CA (1) | CA3048027A1 (https=) |
| CL (1) | CL2019001709A1 (https=) |
| CO (1) | CO2019006622A2 (https=) |
| EA (1) | EA201991503A1 (https=) |
| ES (1) | ES2992411T3 (https=) |
| IL (1) | IL267343B2 (https=) |
| MA (1) | MA47125A (https=) |
| MX (2) | MX392673B (https=) |
| PE (1) | PE20191755A1 (https=) |
| PH (1) | PH12019501212A1 (https=) |
| TN (1) | TN2019000192A1 (https=) |
| TW (1) | TWI795381B (https=) |
| UA (1) | UA127920C2 (https=) |
| UY (1) | UY37537A (https=) |
| WO (1) | WO2018119036A1 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| MX2020003242A (es) | 2017-09-22 | 2020-09-18 | Jubilant Epipad LLC | Compuestos heterociclicos como inhibidores de pad. |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| MX2020006808A (es) | 2017-12-28 | 2020-12-11 | Massachusetts Gen Hospital | Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral. |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| ES2992431T3 (es) * | 2018-06-18 | 2024-12-12 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de MALT1 |
| WO2019243964A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors |
| TW202045008A (zh) * | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途 |
| JP2022523371A (ja) * | 2019-02-22 | 2022-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 医薬製剤 |
| PH12021552018A1 (en) | 2019-02-22 | 2022-09-19 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
| ES2949871T3 (es) | 2019-04-11 | 2023-10-03 | Janssen Pharmaceutica Nv | Anillos de piridina que contienen derivados como inhibidores de MALT1 |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| EP4048659A4 (en) * | 2019-10-24 | 2023-11-29 | ONO Pharmaceutical Co., Ltd. | Modulators of trek (twik related k+ channels) channel function |
| WO2021087086A1 (en) | 2019-10-30 | 2021-05-06 | Biogen Ma Inc. | Condensed pyridazine or pyrimidine as btk inhibitors |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| AU2020385647A1 (en) | 2019-11-22 | 2022-07-14 | Janssen Pharmaceutica Nv | Methods for assessing efficacy of MALT1 inhibitors using an NF-kB translocation assay |
| CN114981453A (zh) * | 2019-11-22 | 2022-08-30 | 詹森药业有限公司 | 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定 |
| WO2021138298A1 (en) * | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| WO2021262969A1 (en) | 2020-06-24 | 2021-12-30 | The General Hospital Corporation | Materials and methods of treating cancer |
| JP2023539729A (ja) * | 2020-08-21 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤の非晶質形態及びその製剤 |
| JP2023538099A (ja) | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
| AU2021361057A1 (en) * | 2020-10-16 | 2023-06-08 | Rarefied Biosciences, Inc. | Malt1 modulators and uses thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US20230414629A1 (en) * | 2020-11-12 | 2023-12-28 | Monopteros Therapeutics, Inc. | Materials and methods of treating cancer |
| GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| WO2022167962A1 (en) * | 2021-02-04 | 2022-08-11 | Aurigene Discovery Technologies Limited | Substituted pyrazolyl compounds as malt-1 inhibitors |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| JP2024508890A (ja) | 2021-03-03 | 2024-02-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 治療有効用量のｍａｌｔ１阻害剤ｊｎｊ－６７８５６６３３（１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－（２－（トリフルオロメチル）ピリジン－４－イル）－１ｈ－ピラゾール－４－カルボキサミド）を使用して状態を治療する方法 |
| CN117120427A (zh) * | 2021-06-18 | 2023-11-24 | 上海拓界生物医药科技有限公司 | 一种malt1抑制剂及其制备方法和用途 |
| WO2023279986A1 (zh) * | 2021-07-05 | 2023-01-12 | 贝达药业股份有限公司 | 六元芳基或杂芳基酰胺类化合物及其组合物和用途 |
| KR20240046170A (ko) | 2021-08-09 | 2024-04-08 | 얀센 파마슈티카 엔브이 | B-세포 악성종양의 치료에 사용하기 위한 조성물 |
| CN113912511B (zh) * | 2021-11-29 | 2024-02-13 | 广东广康生化科技股份有限公司 | 一种联苯肼酯中间体的合成方法 |
| WO2023125877A1 (zh) | 2021-12-30 | 2023-07-06 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
| EP4473966A4 (en) | 2022-02-02 | 2026-01-21 | Ono Pharmaceutical Co | CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT |
| WO2023148501A1 (en) * | 2022-02-03 | 2023-08-10 | C4X Discovery Limited | Heterocyclic derivatives as malt1 inhibitors |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| TW202430031A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| EP4626882A1 (en) | 2022-11-30 | 2025-10-08 | Syngenta Crop Protection AG | Microbiocidal tetrahydroisoquinoline derivatives |
| WO2024125628A1 (zh) * | 2022-12-16 | 2024-06-20 | 江苏恒瑞医药股份有限公司 | 一种Malt 1抑制剂的磷酸酯前药 |
| TW202515873A (zh) * | 2023-06-29 | 2025-04-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種三并環類衍生物抑制劑的晶型及其製備方法 |
| WO2025002340A1 (zh) * | 2023-06-29 | 2025-01-02 | 上海翰森生物医药科技有限公司 | 三并环类抑制剂与抗癌剂在制备抗肿瘤药物中的联合应用 |
| WO2025069270A1 (ja) * | 2023-09-27 | 2025-04-03 | 日本新薬株式会社 | アザインドール化合物及び医薬 |
| AU2024357109A1 (en) | 2023-10-06 | 2026-03-12 | Ionctura Sa | Combination of roginolisib with a malt1-gls inhibitor |
| WO2025114167A1 (en) | 2023-11-28 | 2025-06-05 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025174889A1 (en) * | 2024-02-13 | 2025-08-21 | Board Of Regents, The University Of Texas System | Malt1 and btk dual inhibitors |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025210096A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Fungicidal compositions |
| WO2025210095A1 (en) | 2024-04-03 | 2025-10-09 | Syngenta Crop Protection Ag | Microbiocidal tetrahydroisoquinoline compounds |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| GB9721964D0 (en) * | 1997-10-16 | 1997-12-17 | Pfizer Ltd | Isoquinolines |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| CA2522994C (en) * | 2003-04-30 | 2012-09-25 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer |
| DK1618092T3 (da) | 2003-05-01 | 2011-01-31 | Bristol Myers Squibb Co | Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere |
| WO2006085685A1 (ja) | 2005-02-09 | 2006-08-17 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| CN100526430C (zh) | 2005-10-19 | 2009-08-12 | 中国石油化工股份有限公司 | 一种生产清洁汽油的方法 |
| TW200738682A (en) * | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| ES2336625T3 (es) | 2006-03-22 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos. |
| WO2008008286A2 (en) | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Substituted pyrazoles as ghrelin receptor antagonists |
| WO2008092292A1 (en) | 2007-01-17 | 2008-08-07 | The Hong Kong University Of Science And Technology | Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2 |
| CN101652359A (zh) | 2007-03-09 | 2010-02-17 | 高点制药有限责任公司 | 作为羟类固醇脱氢酶抑制剂的吲哚-和苯并咪唑酰胺类 |
| CN101366715A (zh) | 2007-08-15 | 2009-02-18 | 上海医药工业研究院 | 一种雷帕霉素组合物及其制备方法 |
| US8309523B2 (en) | 2007-11-21 | 2012-11-13 | Vib Vzw | Inhibitors of MALT1 proteolytic activity and uses thereof |
| PL2342196T3 (pl) | 2008-09-24 | 2015-12-31 | Basf Se | Związki pirazolowe do zwalczania szkodników będących bezkręgowcami |
| WO2010039039A1 (en) | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| WO2011036885A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| JP5984801B2 (ja) | 2010-06-22 | 2016-09-06 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | ４−ヒドロキシピリジン類の製造方法 |
| JP2013530199A (ja) | 2010-07-06 | 2013-07-25 | ノバルティス アーゲー | キナーゼ阻害剤として有用な環状エーテル化合物 |
| WO2012063896A1 (ja) | 2010-11-11 | 2012-05-18 | 第一三共株式会社 | 新規ピラゾールアミド誘導体 |
| KR20150020228A (ko) | 2012-05-31 | 2015-02-25 | 에프. 호프만-라 로슈 아게 | 아미노퀴나졸린 및 피리도피리미딘 유도체 |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| BR112015010504A2 (pt) | 2012-11-09 | 2017-12-05 | Univ Cornell | uso de inibidores de molécula pequena de malt1, método de identificação de um modulador de molécula pequena de malt1, e composição farmacêutica |
| WO2014086478A1 (en) | 2012-12-03 | 2014-06-12 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of malt1 protease |
| JP2016508152A (ja) | 2013-01-10 | 2016-03-17 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉ |
| JP2015096499A (ja) * | 2013-10-11 | 2015-05-21 | 田辺三菱製薬株式会社 | 医薬組成物 |
| ES2738695T3 (es) * | 2014-05-28 | 2020-01-24 | Novartis Ag | Nuevos Derivados de Pirazolo Pirimidina y su uso como inhibidores de MALT1 |
| WO2015192081A1 (en) | 2014-06-13 | 2015-12-17 | Byrd, John C. | Biomarker for predicting response of cll to treatment with a btk inhibitor |
| WO2016005994A2 (en) | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires |
| CA2956550A1 (en) | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| EA032030B1 (ru) | 2014-09-10 | 2019-03-29 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы |
| CN107205993B (zh) | 2014-12-06 | 2021-03-09 | 细胞内治疗公司 | 有机化合物 |
| WO2016209688A1 (en) | 2015-06-24 | 2016-12-29 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of cancer and uses thereof |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| WO2017081641A1 (en) | 2015-11-13 | 2017-05-18 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| US10882841B2 (en) | 2016-03-01 | 2021-01-05 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| WO2018020474A1 (en) | 2016-07-29 | 2018-02-01 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| WO2018103060A1 (en) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| ES2856248T3 (es) | 2016-12-21 | 2021-09-27 | Acerta Pharma Bv | Inhibidores de imidazopirazina de la tirosina quinasa de Bruton |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| LT3478719T (lt) | 2016-12-21 | 2021-04-12 | Mereo Biopharma 3 Limited | Antisklerostinų antikūnų naudojimas gydant osteogenesis imperfecta |
| US20200009135A1 (en) | 2017-02-01 | 2020-01-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| WO2018165385A1 (en) | 2017-03-08 | 2018-09-13 | Cornell University | Inhibitors of malt1 and uses thereof |
| WO2018226150A1 (en) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
| MX2020006808A (es) | 2017-12-28 | 2020-12-11 | Massachusetts Gen Hospital | Ubicar al complejo de signalosoma cbm induce a las celulas t reguladoras inflamar al microambiente tumoral. |
| US20210001733A1 (en) | 2018-02-23 | 2021-01-07 | Industrieanlagen-Betriebsgesellschaft Mbh | Device for generating a magnetic field, in particular for an inductive charging system, and primary device of an inductive charging system for dynamically charging vehicles |
| ES2992431T3 (es) | 2018-06-18 | 2024-12-12 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de MALT1 |
| WO2019243964A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyrazole derivatives as malt1 inhibitors |
| JP2022523371A (ja) | 2019-02-22 | 2022-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 医薬製剤 |
| PH12021552018A1 (en) | 2019-02-22 | 2022-09-19 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate |
| ES2949871T3 (es) | 2019-04-11 | 2023-10-03 | Janssen Pharmaceutica Nv | Anillos de piridina que contienen derivados como inhibidores de MALT1 |
| AU2020385647A1 (en) | 2019-11-22 | 2022-07-14 | Janssen Pharmaceutica Nv | Methods for assessing efficacy of MALT1 inhibitors using an NF-kB translocation assay |
| CN114981453A (zh) | 2019-11-22 | 2022-08-30 | 詹森药业有限公司 | 用于评估malt1抑制剂的功效的nf-kb调节的基因表达测定 |
| WO2021138298A1 (en) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| JP2023539729A (ja) | 2020-08-21 | 2023-09-19 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤の非晶質形態及びその製剤 |
| JP2023538099A (ja) | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
| EP4301365A1 (en) | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| JP2024508890A (ja) | 2021-03-03 | 2024-02-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 治療有効用量のｍａｌｔ１阻害剤ｊｎｊ－６７８５６６３３（１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－（２－（トリフルオロメチル）ピリジン－４－イル）－１ｈ－ピラゾール－４－カルボキサミド）を使用して状態を治療する方法 |
-
2017
- 2017-12-19 TW TW106144535A patent/TWI795381B/zh not_active IP Right Cessation
- 2017-12-20 WO PCT/US2017/067516 patent/WO2018119036A1/en not_active Ceased
- 2017-12-20 MA MA047125A patent/MA47125A/fr unknown
- 2017-12-20 PE PE2019001288A patent/PE20191755A1/es unknown
- 2017-12-20 MX MX2019007540A patent/MX392673B/es unknown
- 2017-12-20 US US15/847,999 patent/US10954214B2/en active Active
- 2017-12-20 CA CA3048027A patent/CA3048027A1/en active Pending
- 2017-12-20 EA EA201991503A patent/EA201991503A1/ru unknown
- 2017-12-20 CN CN201780079706.3A patent/CN110214136A/zh active Pending
- 2017-12-20 KR KR1020197021137A patent/KR102583317B1/ko active Active
- 2017-12-20 ES ES17851862T patent/ES2992411T3/es active Active
- 2017-12-20 JP JP2019533465A patent/JP7138641B2/ja active Active
- 2017-12-20 BR BR112019012355A patent/BR112019012355A2/pt not_active Application Discontinuation
- 2017-12-20 UA UAA201908268A patent/UA127920C2/uk unknown
- 2017-12-20 EP EP17851862.7A patent/EP3558969B1/en active Active
- 2017-12-20 AU AU2017382185A patent/AU2017382185C1/en active Active
- 2017-12-20 TN TNP/2019/000192A patent/TN2019000192A1/en unknown
- 2017-12-21 AR ARP170103626A patent/AR110421A1/es not_active Application Discontinuation
- 2017-12-21 UY UY0001037537A patent/UY37537A/es not_active Application Discontinuation
-
2019
- 2019-05-31 PH PH12019501212A patent/PH12019501212A1/en unknown
- 2019-06-13 IL IL267343A patent/IL267343B2/en unknown
- 2019-06-19 CL CL2019001709A patent/CL2019001709A1/es unknown
- 2019-06-21 MX MX2022005827A patent/MX2022005827A/es unknown
- 2019-06-21 CO CONC2019/0006622A patent/CO2019006622A2/es unknown
-
2020
- 2020-11-25 US US17/104,081 patent/US12077521B2/en active Active
-
2022
- 2022-02-28 AU AU2022201352A patent/AU2022201352A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514267A5 (https=) | ||
| AU2017382185C9 (en) | Pyrazole derivatives as MALT1 inhibitors | |
| US10669269B2 (en) | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | |
| CA2762174C (en) | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | |
| US12281122B1 (en) | PI3K inhibitors | |
| JP2019504821A (ja) | ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン | |
| JP2017530960A5 (https=) | ||
| AU2014348191A1 (en) | Tetrahydroquinoline compositions as BET bromodomain inhibitors | |
| RU2017105296A (ru) | Новые соединения | |
| CN111868037B (zh) | 作为crhr2拮抗剂的稠合环状脲衍生物 | |
| US20240109900A1 (en) | Azabicyclic shp2 inhibitors | |
| TW202412783A (zh) | 酪胺酸激酶２抑制劑及其用途 | |
| RU2020134947A (ru) | Производные конденсированной циклической мочевины в антагонист crhr2 |